1. Amgen Inc. (13 from 1,970 patents)

2. Piramal Enterprises Limited (13 from 48 patents)

3. Japan Tobacco Inc. (2 from 1,037 patents)

4. Tularik Limited (1 from 126 patents)

5. Inorbit Therapeutics Ab (1 from 1 patent)

1. 11773077 - Compounds containing carbon-carbon linker as GPR120 agonists

2. 11339153 - Compounds useful in modulating the farnesoid X receptor and methods of making and using the same

3. 11084784 - ROR-gamma modulators and uses thereof

4. 10941133 - Compounds containing carbon-carbon linker as GPR120 agonists

5. 10273230 - Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof

6. 10227360 - Compounds for use as GPR120 agonists

7. 10214521 - Fused heterocyclic compounds as GPR120 agonists

8. 10105373 - Fused triterpene compounds and uses thereof

9. 9475842 - Hexadepsipeptide analogues as anticancer compounds

10. 9062046 - Substituted imidazoquinoline derivatives as kinase inhibitors

11. 8980903 - Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors

12. 8841312 - Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors

13. 8835428 - Diacylglycerol acyltransferase inhibitors

14. 8748426 - Inhibitors of diacylglycerol acyl transferase

15. 8741932 - Imidazopyridine derivatives